Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Apr. 07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
Mar. 31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI

Market Cap	63.66B 55.63B 51.43B 47.51B 89.48B 6,115B 91.1B 613B 241B 2,994B 239B 234B 10,310B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 70.75B 65.41B 60.43B 114B 7,777B 116B 780B 306B 3,808B 304B 297B 13,112B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

Apr. 07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
Mar. 31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
Mar. 30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
Mar. 19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
Mar. 04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
Nov. 12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25-09-25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
25-08-19	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
25-06-30	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
25-02-12	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI
24-10-18	BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)	CI
24-08-27	Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator	CI
24-06-27	Allergan Aesthetics Debuts Alle Payment Plans	CI

24-04-01	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
22-04-20	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
22-04-06	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22-03-22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
21-12-10	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

21-04-20	Planète Bourse : La revue de presse du mardi 20 avril 2021
20-05-07	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
20-05-07	La Chine repart, mais Washington veille
20-05-06	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
20-05-06	Trump franchit le Rubicon

Actavis PLC Stock NYSE

Stocks

US00507K1034

Pharmaceuticals

Valuation: Actavis PLC

Latest news : Actavis PLC

Press Releases: Actavis PLC

News in other languages: Actavis PLC

Managers and Directors: Actavis PLC

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	2016-11-30
Robert Michael PSD	President	55	2020-05-07

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	2020-05-07
Scott Reents BRD	Director/Board Member	-	2020-05-07
Ryan Quigley BRD	Director/Board Member	-	2020-05-07

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-2.48%	-6.72%	+44.19%	+156.43%	1,028B
JOHNSON & JOHNSON	-1.52%	-5.01%	+61.87%	+58.79%	611B
ABBVIE INC.	-1.30%	-3.88%	+27.81%	+79.97%	432B
ROCHE HOLDING AG	+0.05%	-2.24%	+28.39%	+22.07%	323B
NOVARTIS AG	-0.82%	-3.35%	+26.67%	+43.29%	277B
ASTRAZENECA PLC	+0.19%	-12.71%	+18.43%	+21.86%	257B
NOVO NORDISK A/S	+1.01%	-0.29%	-25.61%	-39.89%	217B
AMGEN INC.	-1.44%	-3.49%	+19.60%	+56.20%	192B
GILEAD SCIENCES, INC.	-1.04%	-4.63%	+16.01%	+68.47%	161B
Average	-0.47%	-5.24%	+24.15%	+51.91%	388.7B
Weighted average by Cap.	-0.31%	-5.52%	+33.54%	+76.96%

	2018	2019
Net sales	15.79B 13.8B 12.75B 11.78B 22.19B 1,516B 22.59B 152B 59.67B 743B 59.3B 57.99B 2,557B	16.09B 14.06B 13B 12.01B 22.61B 1,545B 23.02B 155B 60.81B 757B 60.43B 59.1B 2,606B
Net income	-5.1B -4.45B -4.12B -3.8B -7.16B -490B -7.29B -49.1B -19.26B -240B -19.14B -18.72B -825B	-5.27B -4.61B -4.26B -3.93B -7.41B -506B -7.54B -50.78B -19.92B -248B -19.8B -19.36B -854B
Net Debt	21.89B 19.13B 17.68B 16.34B 30.77B 2,103B 31.33B 211B 82.74B 1,030B 82.22B 80.41B 3,545B	17.3B 15.12B 13.98B 12.92B 24.32B 1,662B 24.76B 167B 65.41B 814B 65B 63.56B 2,802B

End-of-day quote NYSE Other stock markets
- ^USD	-